ABIO vs. VNRX, AWH, ICCC, OCX, CDIO, TRIB, BMRA, TKNO, ACHV, and BHG
Should you be buying ARCA biopharma stock or one of its competitors? The main competitors of ARCA biopharma include VolitionRx (VNRX), Aspira Women's Health (AWH), ImmuCell (ICCC), OncoCyte (OCX), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), and Bright Health Group (BHG). These companies are all part of the "medical" sector.
ARCA biopharma (NASDAQ:ABIO) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
56.4% of ARCA biopharma shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 30.9% of ARCA biopharma shares are owned by insiders. Comparatively, 15.4% of VolitionRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ARCA biopharma has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.
In the previous week, ARCA biopharma had 7 more articles in the media than VolitionRx. MarketBeat recorded 7 mentions for ARCA biopharma and 0 mentions for VolitionRx. VolitionRx's average media sentiment score of 0.59 beat ARCA biopharma's score of 0.20 indicating that VolitionRx is being referred to more favorably in the news media.
ARCA biopharma has a net margin of 0.00% compared to VolitionRx's net margin of -4,557.29%. VolitionRx's return on equity of 0.00% beat ARCA biopharma's return on equity.
ARCA biopharma has higher earnings, but lower revenue than VolitionRx. ARCA biopharma is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
VolitionRx has a consensus price target of $2.50, suggesting a potential upside of 180.85%. Given VolitionRx's higher probable upside, analysts clearly believe VolitionRx is more favorable than ARCA biopharma.
ARCA biopharma received 120 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 42.71% of users gave ARCA biopharma an outperform vote while only 33.33% of users gave VolitionRx an outperform vote.
Summary
ARCA biopharma beats VolitionRx on 9 of the 16 factors compared between the two stocks.
Get ARCA biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ARCA biopharma Competitors List
Related Companies and Tools
